Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers01:17

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline moieties. Phenoxybenzamine, with a haloalkylamine...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Becoming Speciesist: How Children and Adults Differ in Valuing Animals by Species and Cognitive Capacity.

Personality & social psychology bulletin·2025
Same author

Will Human-Animal Chimeras Cause Moral Confusion? Exploring Public Attitudes.

Journal of bioethical inquiry·2025
Same author

Medical assistance in dying for mental illness: a complex intervention requiring a correspondingly complex evaluation approach: commentary, Malhi et al.

The British journal of psychiatry : the journal of mental science·2024
Same author

Embodied Neural Systems Can Enable Iterative Investigations of Morally Relevant States.

The Journal of neuroscience : the official journal of the Society for Neuroscience·2024
Same author

The selective deployment of AI in healthcare: An ethical algorithm for algorithms.

Bioethics·2024
Same author

Bioethics' Duty to Conference in Qatar: Reply to Magnus.

The American journal of bioethics : AJOB·2024

Related Experiment Video

Updated: May 17, 2026

Online Repetitive Transcranial Magnetic Stimulation of Dorsomedial and Dorsolateral Prefrontal Cortex in Cognition Decision Making, and Cognitive Dissonance
13:20

Online Repetitive Transcranial Magnetic Stimulation of Dorsomedial and Dorsolateral Prefrontal Cortex in Cognition Decision Making, and Cognitive Dissonance

Published on: December 5, 2025

Beta adrenergic blockade reduces utilitarian judgement.

Sylvia Terbeck, Terbeck Sylvia1, Guy Kahane

  • 1University of Oxford, Department of Experimental Psychology, South Parks Road, Oxford OX1 3UD, England, United Kingdom. sylvia.terbeck@psy.ox.ac.uk

Biological Psychology
|October 23, 2012
PubMed
Summary

Propranolol, a beta-blocker, influences moral decision-making by increasing aversion to personal harm. This suggests noradrenergic pathways are crucial for moral judgment, but not necessarily driven by emotional arousal.

More Related Videos

Measuring Delay Discounting in Humans Using an Adjusting Amount Task
07:47

Measuring Delay Discounting in Humans Using an Adjusting Amount Task

Published on: January 9, 2016

Related Experiment Videos

Last Updated: May 17, 2026

Online Repetitive Transcranial Magnetic Stimulation of Dorsomedial and Dorsolateral Prefrontal Cortex in Cognition Decision Making, and Cognitive Dissonance
13:20

Online Repetitive Transcranial Magnetic Stimulation of Dorsomedial and Dorsolateral Prefrontal Cortex in Cognition Decision Making, and Cognitive Dissonance

Published on: December 5, 2025

Measuring Delay Discounting in Humans Using an Adjusting Amount Task
07:47

Measuring Delay Discounting in Humans Using an Adjusting Amount Task

Published on: January 9, 2016

Area of Science:

  • Neuroscience
  • Moral Psychology
  • Psychopharmacology

Background:

  • Noradrenergic pathways are integral to physiological arousal.
  • Understanding the role of noradrenergic transmission in moral decision-making is crucial.
  • Previous research suggests a link between emotion and moral judgment.

Purpose of the Study:

  • To investigate the influence of noradrenergic transmission on moral decision-making.
  • To examine the effects of propranolol, a beta-adrenoceptor antagonist, on moral judgments.
  • To explore the relationship between noradrenergic activity, emotional arousal, and aversion to harm.

Main Methods:

  • A double-blind, placebo-controlled, parallel group study involving healthy volunteers.
  • Participants were administered propranolol (40 mg orally) or a placebo.
  • Moral dilemmas were presented, contrasting utilitarian outcomes with harmful actions, particularly 'up close and personal' harms.

Main Results:

  • Propranolol significantly reduced heart rate but did not affect self-reported mood.
  • Participants taking propranolol were more likely to deem harmful actions morally unacceptable, especially in personal dilemmas.
  • Response times for personal dilemmas were longer in the placebo group, and judgments were more decisive in the propranolol group.

Conclusions:

  • Noradrenergic pathways significantly influence responses to moral dilemmas.
  • Findings suggest that aversion to harming may not be solely driven by emotional arousal, challenging current theories.
  • The results have practical implications, considering propranolol's widespread use and potential therapeutic applications, such as in PTSD treatment.